The excluded patients had higher aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, and α-fetoprotein (AFP) levels; a higher international normalized ratio (INR); a lower platelet count; a lower albumin level; a lower proportion of HCV infection; a higher proportion of Child–Pugh class B or C; higher fibrosis-4 (FIB-4), ALBI, Model for End-Stage Liver Disease (MELD), and Cancer of the Liver Italian Program (CLIP) scores; a higher BCLC stage and larger tumor size; and a shorter follow-up duration and median OS than the enrolled patients. The gene discussed is GPT; the disease is End Stage Liver Disease.